secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001171843-24-001294
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q4 net loss $27.9M ($0.22/sh); cash $135.7M; HERALD data expected Q4 2024
--------------------------------------------------------------------------------

- Cash and investments $135.7M as of Dec 31, 2023; raised $92.1M in Oct 2023 PIPE; runway through end of 2025.
- Q4 2023 net loss $27.9M ($0.22/sh) vs $21.9M ($0.51/sh) in Q4 2022; full year net loss $87.7M ($1.36/sh).
- ALG-055009 Phase 2a HERALD (MASH) first subject dosed expected Q2 2024; topline data anticipated Q4 2024.
- ALG-000184 (CHB) Phase 1b continues; interim data presentations planned at APASL, EASL, AASLD 2024.
- ALG-097558 pan-coronavirus protease inhibitor Phase 1 nearing completion; topline data at ECCMID April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/0001171843-24-001294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/f8k_031124.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer